These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 22005599)

  • 1. The extracts of Fructus Akebiae, a preparation containing 90% of the active ingredient hederagenin: serotonin, norepinephrine and dopamine reuptake inhibitor.
    Jin ZL; Gao N; Zhou D; Chi MG; Yang XM; Xu JP
    Pharmacol Biochem Behav; 2012 Jan; 100(3):431-9. PubMed ID: 22005599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The antidepressant-like pharmacological profile of Yuanzhi-1, a novel serotonin, norepinephrine and dopamine reuptake inhibitor.
    Jin ZL; Gao N; Li XR; Tang Y; Xiong J; Chen HX; Xue R; Li YF
    Eur Neuropsychopharmacol; 2015 Apr; 25(4):544-56. PubMed ID: 25638027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of norepinephrine and serotonin system in antidepressant-like effects of hederagenin in the rat model of unpredictable chronic mild stress-induced depression.
    Liang BF; Huang F; Wang HT; Wang GH; Yuan X; Zhang MZ; Guo HB; Cheng YF; Xu JP
    Pharm Biol; 2015 Mar; 53(3):368-77. PubMed ID: 25471378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. D-161, a novel pyran-based triple monoamine transporter blocker: behavioral pharmacological evidence for antidepressant-like action.
    Dutta AK; Ghosh B; Biswas S; Reith ME
    Eur J Pharmacol; 2008 Jul; 589(1-3):73-9. PubMed ID: 18561912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of monoamine transporters by common biogenic amines via trace amine-associated receptor 1 and monoamine autoreceptors in human embryonic kidney 293 cells and brain synaptosomes.
    Xie Z; Westmoreland SV; Miller GM
    J Pharmacol Exp Ther; 2008 May; 325(2):629-40. PubMed ID: 18310473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological and behavioral characterization of D-473, an orally active triple reuptake inhibitor targeting dopamine, serotonin and norepinephrine transporters.
    Dutta AK; Santra S; Sharma H; Voshavar C; Xu L; Mabrouk O; Antonio T; Reith ME
    PLoS One; 2014; 9(11):e113420. PubMed ID: 25427177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biaryl analogues of conformationally constrained tricyclic tropanes as potent and selective norepinephrine reuptake inhibitors: synthesis and evaluation of their uptake inhibition at monoamine transporter sites.
    Zhou J; Zhang A; Kläss T; Johnson KM; Wang CZ; Ye YP; Kozikowski AP
    J Med Chem; 2003 May; 46(10):1997-2007. PubMed ID: 12723962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment.
    Verrico CD; Miller GM; Madras BK
    Psychopharmacology (Berl); 2007 Jan; 189(4):489-503. PubMed ID: 16220332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of vesicular uptake of monoamines by hyperforin.
    Roz N; Mazur Y; Hirshfeld A; Rehavi M
    Life Sci; 2002 Sep; 71(19):2227-37. PubMed ID: 12215370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical pharmacology of TP1, a novel potent triple reuptake inhibitor with antidepressant properties.
    Tian JW; Jiang WL; Zhong Y; Meng Q; Gai Y; Zhu HB; Hou J; Xing Y; Li YX
    Neuroscience; 2011 Nov; 196():124-30. PubMed ID: 21925241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Caulis Sinomenii extracts activate DA/NE transporter and inhibit 5HT transporter.
    Zhao G; Bi C; Qin GW; Guo LH
    Exp Biol Med (Maywood); 2009 Aug; 234(8):976-85. PubMed ID: 19491370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine transporter inhibitory and antiparkinsonian effect of common flowering quince extract.
    Zhao G; Jiang ZH; Zheng XW; Zang SY; Guo LH
    Pharmacol Biochem Behav; 2008 Sep; 90(3):363-71. PubMed ID: 18485464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Benzofuran Derivatives Induce Monoamine Release and Substitute for the Discriminative Stimulus Effects of 3,4-Methylenedioxymethamphetamine.
    Johnson CB; Walther D; Baggott MJ; Baker LE; Baumann MH
    J Pharmacol Exp Ther; 2024 Sep; 391(1):22-29. PubMed ID: 38272669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural exploration of (3S,6S)-6-benzhydryl-N-benzyltetrahydro-2H-pyran-3-amine analogues: identification of potent triple monoamine reuptake inhibitors as potential antidepressants.
    Santra S; Gogoi S; Gopishetty B; Antonio T; Zhen J; Reith ME; Dutta AK
    ChemMedChem; 2012 Dec; 7(12):2093-100. PubMed ID: 23060293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs.
    Han DD; Gu HH
    BMC Pharmacol; 2006 Mar; 6():6. PubMed ID: 16515684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological and behavioral analysis of the effects of some bivalent ligand-based monoamine reuptake inhibitors.
    Tamiz AP; Bandyopadhyay BC; Zhang J; Flippen-Anderson JL; Zhang M; Wang CZ; Johnson KM; Tella S; Kozikowski AP
    J Med Chem; 2001 May; 44(10):1615-22. PubMed ID: 11334571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain.
    Rothman RB; Katsnelson M; Vu N; Partilla JS; Dersch CM; Blough BE; Baumann MH
    Eur J Pharmacol; 2002 Jun; 447(1):51-7. PubMed ID: 12106802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cynomorium songaricum extracts functionally modulate transporters of gamma-aminobutyric acid and monoamine.
    Zhao G; Wang J; Qin GW; Guo LH
    Neurochem Res; 2010 Apr; 35(4):666-76. PubMed ID: 20084455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Further structural exploration of trisubstituted asymmetric pyran derivatives (2S,4R,5R)-2-benzhydryl-5-benzylamino-tetrahydropyran-4-ol and their corresponding disubstituted (3S,6S) pyran derivatives: a proposed pharmacophore model for high-affinity interaction with the dopamine, serotonin, and norepinephrine transporters.
    Zhang S; Fernandez F; Hazeldine S; Deschamps J; Zhen J; Reith ME; Dutta AK
    J Med Chem; 2006 Jul; 49(14):4239-47. PubMed ID: 16821783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reboxetine: functional inhibition of monoamine transporters and nicotinic acetylcholine receptors.
    Miller DK; Wong EH; Chesnut MD; Dwoskin LP
    J Pharmacol Exp Ther; 2002 Aug; 302(2):687-95. PubMed ID: 12130733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.